In this #UrologyJournalClub we discuss and summarize the Belzitufan Phase 2 trial for renal masses in patients with Von Hippel-Lindau (VHL) disease published @NEJM which led to the approval of Welireg.
1/8
"men with confirmed M1 castration-resistant prostate cancer (CRPC) whose disease had progressed during treatment with enza or abi, administered for M1 or M0 CRPC or M1 hormone-sensitive prostate cancer. Previous taxane chemotherapy was allowed.”